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Background: Microbiological confirmation of tuberculous meningitis (TBM) remains
problematic. We assessed the diagnostic performance of a modified Ziehl-Neelsen (MZN)
staining method that showed promise in earlier studies.
Methods: Patients evaluated for TBM in Shaanxi province, China, were prospectively
enrolled from May, 2011 to April, 2013. Cerebrospinal fluid (CSF) specimens were
evaluated using the Xpert MTB/RIF® assay, MZN staining, and standard biochemical
and microbiological tests, together with detailed clinical and radiological assessment.
Results: Among 316 patients included in the study, 38 had definite TBM, 66 probable
TBM, 163 possible TBM and 49 “no TBM,” using consensus uniform research case
definition criteria. Comparing “definite or probable TBM” to “no TBM” MZN staining
had higher sensitivity than Xpert MTB/RIF® (88.5 vs. 36.5%), but greatly reduced
specificity (71.4 vs. 100.0%); 14/49 (28.6%) cases with “no TBM” tested positive on
MZN. Mycobacterium tuberculosis culture was performed in 104/179 (58.1%) of MZN
positive samples; 12.5% (13/104) were positive. Using Xpert MTB/RIF® as the reference
standard, MZN had a sensitivity of 92.1% (95% CI 79.2–97.3) and specificity of 71.4%
(95% CI 57.6–82.2).
Conclusion: Xpert MTB/RIF® offered a rapid and specific TBM diagnosis, but sensitivity
was poor. MZN was mainly hampered by false positives. Strategies to enhance the
sensitivity of Xpert MTB/RIF® or improve the diagnostic accuracy of MZN should be
explored.
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INTRODUCTION
Tuberculous meningitis (TBM) represents roughly 1% of all cases
of tuberculosis (TB), but it is responsible for a disproportionate
burden of TB-associated deaths and disability (Thwaites et al.,
2013). Diagnosis of TBM is challenging due to atypical
early clinical manifestations and the low sensitivity of smear
microscopy on cerebrospinal fluid (CSF) specimens. CSF culture
is more sensitive, but takes weeks to yield results and requires
sophisticated laboratory facilities (Koh et al., 2012). Because of
certain death from untreated TBM, a fast and reliable diagnostic
test for TBM is urgently needed.
The Xpert MTB/RIF R© assay uses real-time PCR to identify
pulmonary tuberculosis with a sensitivity of nearly 100% for
smear-positive sputum specimens, around 70% for smear-
negative (culture-positive) specimens, and near 100% specificity
(Nicol et al., 2011). Due to its enhanced sensitivity and ability
to simultaneously detect rifampicin resistance, the World Health
Organization (WHO) recommended that Xpert MTB/RIF R©
replace sputum smear microscopy for initial diagnosis of
suspected human immunodeficiency virus (HIV)-associated TB
(World Health Organization, 2010) WHO also suggested that
Xpert MTB/RIF R© should be considered as the initial diagnostic
test in CSF specimens from patients suspected of having TBM
(World Health Organization, 2013), given its specificity and
rapid turn-around time compared toMycobacterium tuberculosis
culture. A study from South Africa found that CSF Xpert
MTB/RIF R© detected 67% of culture-confirmed TBM cases; 87%
were HIV-infected (Patel et al., 2013). In Vietnam, Nhu and
colleagues reported a sensitivity of 59% (specificity 99%) for CSF
Xpert MTB/RIF R© compared to a clinical TBM case definition;
20.8% of patients were known to be HIV infected (Nhu et al.,
2014). WHO recommends CSF Xpert MTB/RIF R© as an initial
TBM diagnostic test (World Health Organization, 2013) based
primarily on two studies that reported sensitivities of 50–60%
compared toM. tuberculosis culture in patient cohorts with high
rates of HIV coinfection (Patel et al., 2013; Nhu et al., 2014). A
subsequent study demonstrated that TBM diagnostic sensitivity
could be improved using centrifuged CSF (Bahr et al., 2015), but
there is limited data about the sensitivity of Xpert MTB/RIF R© in
HIV uninfected patients.
Modified Ziehl-Neelsen staining (MZN) showed great
promise to assist the quick identification of TBM cases. Initial
proof-of-concept studies demonstrated greatly improved
detection rates, of both extracellular and intracellular
mycobacteria, compared to conventional ZN staining (Chen
et al., 2012). In a clinical study conducted in China the sensitivity
of MZN (82.9%) was found to be significantly higher than
conventional ZN staining (3.3%), which had very poor sensitivity
(Feng et al., 2014). Since M. tuberculosis is an intracellular
pathogen and the numbers of extra-cellular bacteria are few in
CSF, the ability to stain intracellular and extracellular bacteria
was considered the most likely explanation for the increased
sensitivity observed with MZN (Thwaites, 2013). However,
more rigorous assessment is required to confirm the diagnostic
value of MZN and to assess its performance compared to Xpert
MTB/RIF R© for rapid TBM diagnosis.
METHODS
Study Design and Setting
We performed a prospective descriptive study enrolling all
suspected TBM patients over a 2 year period (May 2011–April
2013). The study was coordinated from Xijing hospital of the
Fourth Military Medical University; the largest medical center in
Shaanxi province, China. All tertiary referral hospitals in Shaanxi
province (11 in total) participated in the study. Shaanxi province
is located in Northwestern China and has a population of 36.7
million people, a TB notification rate of 109/100,000 population
(Zhang et al., 2011)1 and a low human immunodeficiency virus
(HIV) prevalence (<1% of TB patients) (Zhao et al., 2014).
Patients were eligible for inclusion if they had symptoms of
meningitis (fever, headache, seizure, vomiting, nuchal rigidity,
or abnormal CSF parameters) and provided written informed
consent to participate.
Clinical Data
Patients were retrospectively scored according to the British
Medical Research Council TBM severity grade (British Medical
Research Council, 1948) and classified according to consensus
uniform research case definition criteria (Marais et al., 2010),
as “definite”, “probable,” or “possible” TBM (Table 1). Since the
study aimed to evaluate the diagnostic performance of MZN,
MZN was not included in the classification. The “not TBM”
category was sub-divided into cases of infectious neurological
disorders (IND) and non-infectious neurological disorders
(NIND). All patients were tested for HIV (Roche Elecsys HIV
Combi, Basel, Switzerland). Additional information was gathered
from reviewing relevant clinical notes. Patients were excluded if
their clinical data were incomplete or consent for participation
was not obtained.
Specimen Collection and Processing
All patients received a lumbar puncture for CSF collection;
standard biochemical and microbiological analyses were
performed, including India ink staining. CSF M. tuberculosis
culture was performed using the MGIT960 system according
to standard protocol (Krüüner et al., 2006), depending on
availability and the discretion of the treating physician.
CSF specimens were sent to Xijing Hospital where MZN
was performed by experienced technicians, blinded to all
other information. MZN staining used 0.5ml of CSF loaded
into a cytospin chamber with poly-lysine-coated slides and
centrifuged at 1000 × g for 5min. The slide was fixed with
4% paraformaldehyde for 15min at room temperature then
permeabilized with 0.3% TritonX-100 for 30min, before
staining with carbolfuchsin containing 0.3% TritonX-100 and
counterstained with methylene blue. All slides stained by the
modified method were observed under oil immersion at a
magnification of 1000 (Chen et al., 2012). Three hundred fields
on each slide were examined documenting the number of fields
in which acid fast bacilli were observed, as well as their intra-
or extra-cellular location. Positive slides were confirmed by
1The tuberculosis control program in Shaanxi province, China. Available online at:
http://wenku.baidu.com/view/0ce7d938580216fc700afd6c.html
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TABLE 1 | Diagnostic criteria and scores assigned by the uniform TBM research case definition (Marais et al., 2010).
Diagnostic criteria Score
CLINICAL (MAXIMUM CATEGORY SCORE = 6)
Symptom duration of more than 5 days 4
Systemic symptoms suggestive of TB (1 or more of): weight loss/(poor weight gain in children), night sweats or persistent cough >2 weeks 2
History of recent close contact with an individual with pulmonary TB or a positive TST/IGRA in a child <10 years 2
Focal neurological deficit (excluding cranial nerve palsies) 1
Cranial nerve palsy 1
CSF (MAXIMUM CATEGORY SCORE = 4)
Clear appearance 1
Cells: 10–500 per µl 1
Lymphocytic predominance (>50%) 1
Protein concentration greater than 1 g/L 1
CSF to plasma glucose ratio of less than 50% or an absolute CSF glucose concentration less than 2.2 mmol/L 1
CEREBRAL IMAGING (CT AND/OR MRI) (MAXIMUM CATEGORY SCORE = 6)
Hydrocephalus 1
Basal meningeal enhancement 2
Tuberculoma 2
Infarct 1
Pre-contrast basal hyperdensity 2
EXTRANEURAL TB (MAXIMUM CATEGORY SCORE = 4)
Chest radiograph suggestive of active TB (excludes miliary TB) 2
Chest radiograph suggestive of miliary TB 4
CT/MRI/US evidence of TB outside the CNS 2
AFB identified or M. tuberculosis cultured from another source i.e., sputum, lymph node, gastric washing, urine, and blood culture 4
Exclusion of alternative diagnoses- An alternative diagnosis must be confirmed microbiologically, serologically or histopathologically
Definite TBM = AFB seen on CSF microscopy, positive CSF M. tuberculosis culture, or positive CSF M. tuberculosis commercial NAAT in the setting of symptoms/signs
suggestive of meningitis; or AFB seen in the context of histological changes consistent with TB brain or spinal cord together with suggestive symptoms/signs and CSF
changes, or visible meningitis (on autopsy).
Probable TBM = Total score of ≥12 if neuroimaging available (total score of ≥10 if unavailable)
Possible TBM = Total score of 6–11 if neuroimaging available (total score of 6–9 if unavailable)
Not TBM = Alternative diagnosis established, without a definitive diagnosis of tuberculous meningitis or other convincing signs of dual disease.
TBM, tuberculous meningitis; TB, tuberculosis; TST, tuberculin skin test; IGRA, interferon gamma-release assay; CSF, cerebrospinal fluid; CT, computed tomography; MRI, magnetic
resonance imaging; CNS, Central Nervous System; US, ultrasound; AFB, acid-fast bacilli; NAAT, nucleic acid amplification test.
independent review from another technician; 25% of slides were
randomly selected for rereading (Feng et al., 2014).
All remaining CSF was stored at −80◦C (at most 2 years)
and then transferred on dry ice to the National Tuberculosis
Reference Laboratory of the Chinese Center for Disease Control
and Prevention in Beijing to perform Xpert MTB/RIF R©
(Cepheid, Sunnyvale, CA, USA) testing using centrifugation
(1000 rpm for 10 min) of CSF volumes (median: 1mL, range:
1–2 mL), according to standard protocol (Boehme et al., 2010).
All tests were performed by experienced technicians who were
blinded to the patients’ diagnostic results.
Statistical Analysis and Ethics
Statistical analysis was performed using SPSS v.15.0 (SPSS
Inc., Chicago, IL, USA) and GraphPad Prism v.5.0 (GraphPad
Software Inc., La Jolla, CA). Categorical variables were compared
using X2 test if they were independent or McNemar’s test if they
were paired. Differences with p-values < 0.05 were considered
statistically significant. The study protocol was approved by the
Ethics Committee of Xijing Hospital (Fourth Military Medical
University—study number KY20105255-1). Written informed
consent was obtained from all participants or their legal
guardians.
RESULTS
In total, 334 patients were included in the study, but 18 patients
had to be excluded due to incomplete data (n= 10) or inadequate
consent (n = 8). (Figure 1) Of the 316 patients included in
the analysis, 38 (12.0%) were classified as definite TBM, 66
(20.9%) as probable TBM, and 163 (51.6%) as possible TBM.
Of the 49 (15.5%) cases with an alternative diagnosis that were
classified as “not TBM,” 38 (77.6%) had an infectious and 11
(22.4%) a non-infectious cause. The infectious disease (IND)
group included bacterial meningitis (n = 11), cryptococcal
meningitis (n = 18), and 9 cases of aseptic meningitis. The non-
infectious disease (NIND) group included meningioma (n = 3),
Guillain-Barre syndrome (n = 2), cerebral hemorrhage (n = 2),
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FIGURE 1 | Flow diagram of patients evaluated for tuberculous meningitis. TBM, tuberculosis meningitis; MZN, modified Ziehl-Neelsen staining; IND,
infectious neurological disorder other than tuberculosis; NIND, non-infectious neurological disorder. *Classification according to the consensus uniform research case
definition criteria (Marais et al., 2010).
acute lymphoblastic leukemia (n = 1), acute non-lymphocytic
leukemia (n = 1), non-Hodgkin lymphoma (n = 1), and
obstructive hydrocephalus (n = 1). Three cases with alternative
diagnoses (2 meningioma, 1 acute non-lymphocytic leukemia)
tested positive by both MZN and Xpert MTB/RIF R©; they were
classified as “definite” TBM cases and received standard anti-TB
treatment (isoniazid, rifampicin, pyrazinamide, ethambutol).
The cohort had a median age of 31 years (range 1–80), and the
majority (62.3%) of patients were male. All patients were HIV-
uninfected. Table 2 provides an overview of relevant clinical,
central nervous system imaging, and CSF findings. Among the
316 suspected TBM patients, 38 (12.0%) tested positive with
Xpert MTB/RIF R©, and 179 (56.7%) with MZN staining; 35
(11.1%) tested positive with both methods.
Table 3 summarizes the diagnostic accuracy observed with
MZN and Xpert MTB/RIF R©, using “definite or probable
TBM” and “definite, probable or possible TBM” as reference
standards. With this approach the diagnostic sensitivity of MZN
(88.5%; 95% confidence interval 80.9–93.3 and 61.8%; 95% CI
55.8–67.4, respectively) appeared higher than that of Xpert
MTB/RIF R© (36.5%; 95% CI 27.9–46.1 and 14.2%; 95% CI 10.6–
18.9, respectively), but the specificity compared to “definite or
probable TBM” and “definite, probable or possible TBM” was
lower (71.4%; 95% CI 57.6–82.2 vs. 100.0%; 95% CI 92.7–100.0).
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TABLE 2 | Baseline characteristics of patients evaluated for tuberculous meningitis.
Baseline characteristics TBM Not TBM
Definite
N = 38 (%)
Probable
N = 66 (%)
Possible
N = 163 (%)
IND
N = 38 (%)
NIND
N = 11 (%)
Age (years)* 25 (7–72) 35 (2–64) 29 (1–80) 34.5 (7–77) 39 (5–57)
Female sex 18 (47) 32 (49) 53 (33) 12 (32) 4 (36)
HISTORY
Fever 24 (63) 54 (82) 113 (69) 26 (68) 3 (27)
Headache 28 (74) 56 (85) 109 (67) 25 (66) 4 (36)
Vomiting 20 (53) 39 (59) 85 (52) 19 (50) 4 (36)
Seizures 2 (5) 10 (15) 27 (17) 4 (11) 1 (9)
Previous TB 2 (5) 3 (5) 2 (1) 0 0
BMRC GRADINGa
I 15 (40) 27 (41) 85 (52)
II 5 (13) 7 (11) 36 (22)
III 18 (47) 32 (49) 42 (26)
Diagnostic score* 14 (10–18) 12 (10–16)b 8 (6–11)c 8 (3–15) 4 (3–9)
IMAGING
Chest X-ray suggestive of TB 14 (37) 23 (35) 19 (12) 6 (16) 1 (9)
Hydrocephalus 9 (24) 13 (20) 15 (9) 2(5) 1 (9)
Basal meningeal enhancement 9 (24) 8 (12) 16 (10) 5 (13) 0
Infarcts 9 (24) 17 (26) 17 (10) 7 (18) 0
CSF FINDINGS
Total leukocyte count* cells/µl 124 (0–6100) 94 (0–1355) 96 (0–5450) 45 (1–3470) 5 (0–1240)
Neutrophils (%)* 23 (0–95) 7 (0–95) 2 (0–94) 2 (0–88) 20 (3–63)
Lymphocytes >50% 24 (63) 52 (79) 114 (70) 30 (79) 8 (73)
Monocytes (%)* 10(3–27) 8(0–47) 11 (0–85) 12 (3–51) 21 (8–83)
Glucose <2.2 mmol/l 15 (40) 38 (58) 36 (22) 13 (34) 1 (9)
Protein >1.0 mg/dl 20 (53) 43 (65) 47 (29) 17 (45) 1 (9)
TBM, tuberculous meningitis; TB, tuberculosis; IND, infectious neurological disorders; NIND, non-infectious neurological disorders; CSF, Cerebral Spinal Fluid.
*Median (range); aBMRC grading—British Medical Research council disease severity grade (British Medical Research Council 1948): stages 1, 2, and 3 were characterized by signs of
meningitis with no neurological deficits, focal neurological deficits, and stupor or coma, respectively; bScores of 10 and 11 when brain imaging was not available; cScores of 10 and 11
when brain imaging was available.
CSF M. tuberculosis culture was performed in 201/316 (63.6%)
patients; none classified as “Not TBM.” Culture was performed
in 104/179 (58.1%) MZN positive samples; 12.5% (13/104)
were confirmed as M. tuberculosis and no nontuberculous
mycobacteria (NTM) were identified. Of the CSF culture positive
specimens, 61.5% (8/13) were confirmed as M. tuberculosis by
Xpert MTB/RIF R©. Using MGIT960 culture as the reference
standard, MZN had a sensitivity of 100.0% (95% CI 77.2–100.0)
compared to 61.5% for Xpert MTB/RIF R© (95%CI 35.5–82.3),
but the specificity was lower (51.6%; 95%CI 44.5–58.6 vs. 98.9%;
95%CI 96.2–99.7). Using Xpert MTB/RIF R© as the reference
standard, MZN had a sensitivity of 92.1% (95% CI 79.2–97.3) and
specificity of 71.4% (95% CI 57.6–82.2).
MZN was positive in 14 (28.6%) patients classified as “not
TBM.” Table 4 summarizes the clinical profile and outcome of
patients in whom a “false positive” MZN test result was recorded.
Alternative diagnoses established included cryptococcal (6 cases)
and bacterial (6 cases) meningitis, meningioma (1 case) and acute
lymphoblastic leukemia (1 case). One patient with cryptococcal
meningitis died, but all other patients achieved good outcomes
despite only 4/13 (30.7%) receiving anti-tuberculosis treatment.
The patient who died had highly elevated intra-cranial pressure
and rapidly progressive disease attributed to cryptococcal
meningitis. Although the CSF was MZN positive, the Xpert
MTB/RIF R© test was negative and there was no suggestion of
extra-neural TB; no CSF culture was performed and no anti-
tuberculosis treatment provided.
DISCUSSION
Our findings confirm the high specificity of the XpertMTB/RIF R©
assay, but the sensitivity was poor; detecting less than half the
patients with “confirmed or probable” TBM. The sensitivity of
the Xpert MTB/RIF R© assay may have been adversely affected
by cold storage and delayed testing, as well as the low sample
volumes and low bacterial load in CSF samples. The yield
reported in our study is generally comparable to previous TBM
studies (Alvarez-Uria et al., 2012; Patel et al., 2013; Bahr et al.,
2015), although a study in Uganda reported that the Xpert
MTB/RIF R© yield more than doubled (72 vs. 28%) using high
volume centrifuged CSF specimens (Bahr et al., 2015). Studies
reporting higher sensitivity with XpertMTB/RIF R© often enrolled
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TABLE 3 | Diagnostic accuracy of MZN stain compared to “definite or probable TBM,” “definite, probable, or possible TBM,” CSF M. tuberculosis culture
or CSF Xpert MTB/RIF® as reference standards.
Reference standard MZN Xpert MTB/RIF®
+ − + −
Definite or probable TBM* (N = 104) 92 12 38 66
Not TBM (N = 49) 14 35 0 49
Definite, probable or possible TBM* (N = 267) 165 102 38 229
Not TBM (N = 49) 14 35 0 49
CSF M. tuberculosis culture positivie** (N = 13) 13 0 8 5
CSF M. tuberculosis culture negative** (N = 188) 91 97 2 186
Xpert MTB/RIF® confirmed (N = 38) 35 3 38 0
Not TBM (N = 49) 14 35 0 49
Reference standard Diagnostic performance measure MZN (%) 95%CI Xpert MTB/RIF® (%) 95%CI
Definite, or probable TBM* Sensitivity 88.5 (92/104) 80.9–93.3 36.5 (38/104) 27.9–46.1
Specificity 71.4 (35/49) 57.6–82.2 100.0 (49/49) 92.7–100.0
PPV 86.8 (92/106) 79.0–92.0 100.0 (38/38) 90.8–100.0
NPV 74.5 (35/47) 60.5–85.0 42.6 (49/115) 34.0–51.7
Definite, probable or possible TBM* Sensitivity 61.8 (165/267) 55.8–67.4 14.2 (38/267) 10.6–18.9
Specificity 71.4 (35/49) 57.6–82.2 100.0 (49/49) 92.7–100.0
PPV 92.2 (165/179) 87.3–95.3 100.0 (38/38) 90.8–100.0
NPV 25.5 (35/137) 19.0–33.5 17.6 (49/278) 13.6–22.5
Positive CSF M.tuberculosis culture** Sensitivity 100.0 (13/13) 77.2–100.0 61.5 (8/13) 35.5–82.3
Specificity 51.6 (97/188) 44.5–58.6 98.9 (186/188) 96.2–99.7
PPV 12.5 (13/104) 7.5–20.2 80 (8/10) 49.0–94.3
NPV 100.0 (97/97) 96.2–100.0 97.4 (186/191) 94.0–98.9
Xpert MTB/RIF® confirmed Sensitivity 92.1 (35/38) 79.2–97.3 N/A
Specificity 71.4 (35/49) 57.6–82.2
PPV 71.4 (35/49) 57.6–82.2
NPV 92.1 (35/38) 79.2–97.3
TBM, tuberculosis meningitis; MZN, modified Ziehl-Neelsen staining; CSF, cerebral spinal fluid; PPV, Positive Predictive Value; NPV, Negative Predictive Value; 95%CI-95% confidence
interval; N/A, not applicable; M. tuberculosis, Mycobacterium tuberculosis.
*Classification according to the consensus uniform research case definition criteria (Marais et al., 2010).
**CSF M. tuberculosis culture was performed in only 201/316 (63.6%) patients; depending on culture availability and the discretion of the treating physician.
high proportions of HIV-infected patients (Patel et al., 2013; Nhu
et al., 2014; Bahr et al., 2015), while no patients wereHIV-infected
in our study. Although a positive Xpert MTB/RIF R© assay result
provided a rapid and specific diagnosis, the sensitivity of the
Xpert MTB/RIF R© assay is not good enough to serve as a “rule
out” test (Bahr et al., 2016).
MZN previously demonstrated excellent sensitivity (100%)
and good specificity (85.1%) compared to culture-confirmed
TBM as the reference standard, suggesting value as a rapid
screening test (Feng et al., 2014). However, in the current study
MZN results suggested a high number of false positives, with only
12.5% of cultured MZN positive CSF specimens confirmed as
M. tuberculosis and 28.6% of “not TBM” patients found to be
MZN positive. MZN specificity was 71.4% compared to Xpert
MTB/RIF R© as the reference standard. The fact that a large
number of patients who were not “confirmed or probable” TBM
cases were MZN positive is a concern, since false positive tests
may lead to unnecessary and inappropriate treatment. This is
particularly true for the “not TBM” cases in whom an alternative
diagnosis was established; most of whom recovered without
anti-tuberculosis treatment. Although, many of these patients
received short courses of ceftriaxone and/or meropenem, which
may have some anti-tuberculosis activity, there is no ancillary
evidence to support the positive MZN result and it is highly
unlikely that the sub-optimal treatment received would have
resulted in cure if these patients had TBM.
The poor specificity observed with MZN could be explained
by superior sensitivity compared to the reference standard, but
this is unlikely to apply to the clinical reference standard used,
given that only “definite and probable TBM” and “not TBM”
cases were included in the comparative analysis. Nontuberculous
mycobacteria (NTM) may also explain discrepant MZN and
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TABLE 4 | Clinical profile, treatment and outcome of 14 patients with positive MZN staining of their cerebrospinal fluid classified as “not TBM”.
Gender Age (years) Outcome Final diagnosis TBM score* TBM treatment** Other antibiotics
M 30 Good Cryptococcal meningitis 9 Y ceftriaxone, fluconazole
M 7 Good Cryptococcal meningitis 10 N ceftriaxone, meropenem, fluconazole
F 49 Good Meningeoma 9 N –
M 68 Good Cryptococcal meningitis 15 Y fluconazole
F 17 Good Bacterial meningitis 11 N ceftriaxone, meropenem, vancomycin
M 54 Good Bacterial meningitis 9 N ceftriaxone
M 61 Good Bacterial meningitis 10 N ceftriaxone, vancomycin
M 25 Good Bacterial meningitis 10 N ceftriaxone
M 5 Good Acute lymphoblastic leukemia 7 N ceftriaxone
F 11 Good Bacterial meningitis 8 N ceftriaxone
M 39 Good Cryptococcal meningitis 9 Y ceftriaxone, fluconazole
M 18 Good Cryptococcal meningitis 8 Y ceftriaxone, fluconazole
M 43 Dead Cryptococcal meningitis 9 N fluconazole
M 33 Good Bacterial meningitis 10 N ceftriaxone, meropenem, ciprofloxacin
MZN, Modified Ziehl-Neelsen; TBM, tuberculous meningitis; M, Male; F, Female; Y, yes; N, no; *Score according to the consensus uniform research case definition criteria (Marais et al.,
2010); **Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol; All patients were HIV-uninfected.
Xpert MTB/RIF R© results (Menzies and Nahid, 2013), but
NTM is an exceedingly rare cause of meningitis (Lawn and
Zumla, 2011) and no NTM was identified in any of the
samples that grewmycobacteria. Artifacts produced duringMZN
staining may have been misidentified as mycobacteria, since
the technique often distorts the typical appearance of acid-
fast bacilli (Chen et al., 2012). Although highly experienced
laboratory technicians performed the staining and interpreted
the results, the technique may benefit from careful optimization.
In general, the positive predictive value of MZN was lower
than that of Xpert MTB/RIF R©, but the negative predictive value
was higher indicating potential value as a preliminary screening
test. However, the fact that MZN had a sensitivity of 92.1%
compared to Xpert MTB/RIF R© limits its use as a rapid screening
test in its current format, given fears of potential false negative
results.
Study limitations include the fact that M. tuberculosis culture
was performed on a minority of patients. M. tuberculosis culture
would have had particular value in potentially false positive
MZN cases that tested negative on Xpert MTB/RIF R©. The
absence of an optimal reference standard that is inclusive
of all “true TBM” cases remains problematic and hampers
diagnostic test development. Given the current limitations,
assessing the diagnostic performance of new tests against
multiple reference standards, as done in our study, represents
the most rigorous approach. There is a huge need for a
triage test with high sensitivity that could rapidly screen
potential TBM cases. Despite good sensitivity, the fact that
some Xpert MTB/RIF R© positive cases were MZN negative
is a major concern. Once MZN methodology has been
reviewed and optimized it should be re-evaluated in a large
prospective study with well characterized patient groups,
to specifically explore it value as a rapid, sensitive triage
test.
CONCLUSION
A positive CSF Xpert MTB/RIF R© result provides a rapid and
specific TBM diagnosis, but poor sensitivity is a major constraint.
MZN is hampered by likely false positives and sub-optimal
specificity. Given its increased sensitivity compared to Xpert
MTB/RIF R©, MZN could be considered as a rapid triage test,
but potential false negative results require further evaluation.
Strategies to enhance the sensitivity of Xpert MTB/RIF R© or
improve the diagnostic accuracy of MZN should be explored.
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